Sugi Predict

Sugi Predict / Compounds / SCHEMBL719899

SCHEMBL719899

SCHEMBL719899

Cc1nn(-c2ccc(Cl)cc2)cc1C(Nc1ccc(C(=O)N(C)CCC(=O)O)cc1)C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GCG P01275 10/20 0.45
▸ GLP1R P43220 1/20 0.39
▸ GCGR P47871 1/20 0.39
▸ GIPR P48546 1/20 0.39
▸ KMT2A Q03164 3/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ AGTR1 P30556 1/20 0.36
▸ RCE1 Q9Y256 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ AURKA O14965 1/20 0.34
▸ NR1H4 Q96RI1 2/20 0.34
▸ SLC6A9 P48067 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718414 0.93 GCG (0.43) GCGGLP1RGCGRGIPRKDM4E
SCHEMBL720570 0.92 GCG (0.44) GCGGLP1RGCGRGIPRKMT2A
SCHEMBL717855 0.91 SLC6A9 (0.42) GCGGLP1RGCGRGIPRKMT2A
SCHEMBL721092 0.90 GCGR (0.51) GCGGLP1RGCGRGIPR
SCHEMBL718602 0.88 GCGR (0.45) GCGGLP1RGCGRGIPRKMT2A
SCHEMBL720562 0.87 GCG (0.41) GCGGLP1RGCGRGIPRRCE1
SCHEMBL717929 0.87 GCG (0.46) GCGGLP1RGCGRGIPRKMT2A
SCHEMBL720658 0.86 GCG (0.60) GCGGLP1RGCGRGIPR
SCHEMBL720391 0.86 GCG (0.40) GCGGCGRKMT2ARCE1MEN1
SCHEMBL721260 0.84 CASP3 (0.38) GCGRCE1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 — — US disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 — — US disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 — — US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 — — US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 — — US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 — — US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 — — US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 — — US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 — — US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 — — EP disclosed
WO-2009110520-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP GCG 35/4885GLP1R 5/4885GCGR 90/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP GCG 35/4885GLP1R 5/4885GCGR 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.